What is a contamination control strategy (CCS) under EU GMP Annex 1, and what should it contain?

1What a contamination control strategy is.

EU GMP Annex 1, in operation since 25 August 2023, defines a contamination control strategy (CCS) as “a planned set of controls for microorganisms, endotoxin/pyrogen and particles, derived from current product and process understanding that assures process performance and product quality.” The controls can cover materials and components, facility and equipment operating conditions, in-process controls, finished product specifications and the methods and frequency of monitoring.¹

Section 2.3 says what the CCS is for. It “should be implemented across the facility in order to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to medicinal product quality and safety.” Together, those controls “should establish robust assurance of contamination prevention.”¹

Annex 1 sets the order of priority for quality risk management in 2.2: first the design of the facility, equipment and processes, then well-designed procedures, and finally monitoring, which shows that the design and procedures work. “Monitoring or testing alone does not give assurance of sterility.”¹ No terminal process or finished product test should be relied on alone for sterility or other quality aspects (2.7).¹

2What a CCS should contain.

Annex 1 says developing a CCS “requires detailed technical and process knowledge”, and lists the elements it should consider, “but are not limited to” (2.5).¹

Contamination sources include microbial and cellular debris, such as pyrogen and endotoxin, and particles, such as glass and other visible and sub-visible particles.¹ Annex 1 also asks that the risk management behind the CCS be documented, “including the rationale for decisions taken in relation to risk reduction and acceptance of residual risk” (3.1).¹

3Where the CCS decides the details.

Much of Annex 1 refers decisions to the CCS, so the strategy has to hold the reasoning behind them. Examples include:¹

• whether RABS or isolators are used, and the justification for any alternative (4.3);
• the background grade around an isolator, which should be justified in the CCS (4.20);
• whether grade A and B classification includes ≥5 µm particles (4.27);
• unidirectional airflow speeds outside the 0.36 to 0.54 m/s guidance value, where scientifically justified (4.30);
• whether disinfectants used in grade C and D must be sterile (4.35);
• water system sampling, which “should reflect the requirements of the CCS” (6.13);
• the acceptance criteria, monitoring and effectiveness review for aseptic process controls (8.7);
• the number of units filled in an aseptic process simulation (9.40).

The environmental and process monitoring programme “forms part of the overall CCS” (9.1). Annex 1 adds that viable monitoring, total particle monitoring and aseptic process simulation each have limited reliability taken in isolation, and that together they help confirm the design, validation and operation of the system.¹

4How the CCS is reviewed and changed.

The CCS “should be actively reviewed and, where appropriate, updated and should drive continual improvement”, and its effectiveness should be part of the periodic management review (2.3). Changes to systems should be assessed for any impact on the CCS “before and after implementation” (2.6). Existing control systems that are well managed need not be replaced, but should be referenced in the CCS, with their interactions understood.¹

PIC/S, EMA and WHO answered common questions in PI 058-1, in force from 28 October 2026, which states it introduces no new GMP requirements.²

5Where the requirement applies.

The same text is Annex 1 of the PIC/S GMP Guide, adopted on 9 September 2022 and in force from 25 August 2023.² WHO’s 2022 GMP for sterile pharmaceutical products, revised with the EU and PIC/S, calls for a CCS across the facility in nearly the same terms.³ Annex 1 also allows its CCS principles to support non-sterile products where control of contamination matters, such as certain liquids, creams, ointments and low-bioburden biological intermediates.¹

FDA’s CGMP regulations and its 2004 aseptic processing guidance don’t use the term. 21 CFR 211.113(b) requires written procedures “designed to prevent microbiological contamination of drug products purporting to be sterile”, including validation of all aseptic and sterilisation processes.⁴⁵

6How it runs in Seal.

In Seal, the contamination control strategy links contamination risks, their routes and barriers to the controls that address them, and each control to the monitoring, qualification and investigation evidence behind it. Each control states what it prevents or detects, its acceptance criteria, its evidence and who responds when it fails, so the strategy shows where it relies on a single weak or unverified control. A change cannot close until the affected CCS links and narrative are reviewed. The manufacturer defines the scientific strategy; Seal maintains the evidence network behind it.

Monitoring and cleaning evidence is recorded in Seal too: environmental monitoring keeps each sample with its location, collection window, media and incubation, and cleanroom cleaning and disinfection records each clean against the room’s zones and surfaces, the prepared agent and the contact time.